Press release
University of Dundee spinout Amphista Therapeutics has received a boost in its efforts to develop new drugs for neurogenerative diseases such as dementia.
Press release
University of Dundee spinout Amphista Therapeutics has received a boost in its efforts to develop new drugs for neurogenerative diseases such as dementia.
Press release
A successful collaboration between the University of Dundee and pharmaceutical company Eisai Co Ltd aiming to create innovative new cancer drugs has been extended for a further three years.
Press release
A University of Dundee expert has been named as one of the rising stars of European science.
Press release
An international collaboration, featuring scientists from the University of Dundee, has made a breakthrough they hope will help futureproof a revolutionary new field of drug discovery by preventing resistance in cancer therapy.
Press release
Scientists have designed a novel molecule capable of destroying an as-yet undruggable cancer-causing protein – and are making it available for researchers around the world to use in their own work, free of charge
Press release
University of Dundee spinout Amphista Therapeutics has been designated as one of the world’s most promising biotechnology companies.
Press release
Researchers from the University of Dundee have discovered a small molecule that helps to eliminate a Parkinson’s disease-causing protein
Feature
Early career researchers in the School have received support from the Scottish Universities Life Sciences Alliance (SULSA) to establish new life sciences networks by providing funds towards the running of a network event.
Press release
The University of Dundee and Bio-Techne, a global life sciences company providing innovative tools and bioactive reagents, will partner to commercialise technology developed at Dundee that enhances the understanding of undruggable diseases.
Press release
All roads lead west for a University of Dundee scientist who is using pedal power to fund research into Parkinson’s disease.
Press release
University of Dundee spinout Amphista Therapeutics will work with global biopharmaceutical companies as part of strategic collaborations potentially worth more than $2 billion.
Press release
Mutations in PINK1 are the second most frequent cause of autosomal recessive early-onset Parkinson’s disease.